Hypoxia-inducible Adenovirus Vector Construction Service
Creative Biolabs is a leading expert in adenovirus vector construction for gene delivery and gene therapy applications. Based on powerful viral vector construction technologies and abundant experience, we offer a broad range of adenovirus vector construction service at a reasonable cost and quick turnaround time.
Introduction of Hypoxia-induced Expression System
Hypoxia (lowered oxygen conditions) is a common feature of ischemic heart disease and is associated with resistance to anticancer radio- and chemotherapy. More importantly, tumor hypoxia appears to accelerate malignant progression and increase metastasis. Hypoxia is regulated by the hypoxia-inducible factor (HIF), which activates gene expression by binding to the hypoxic-response elements (HREs) within the promoter regions of genes, which regulate biological processes. HIF is a transcription factor that regulates gene expression in response to hypoxia. As a heterodimeric complex, it is composed of an oxygen-sensitive α subunit and a constitutively expressed β subunit. Expression systems with HREs, which are activated by HIF1α, can be exploited for the development of cancer therapeutics targeting tumor hypoxia. In fact, a number of expression systems with HREs have been designed for tumor- or disease-specific gene expression.
Scientific Foundation: The Mechanism of Hypoxia Induction
To understand our construction process, one must look at the HIF (Hypoxia-Inducible Factor) pathway.
Our vectors are engineered with a synthetic promoter containing multiple tandem repeats of the Hypoxia-Response Element (HRE)—typically the 5'-RCGTG-3' consensus sequence derived from the erythropoietin (EPO) or VEGF genes.
- Under Normoxia: HIF-1α is hydroxylated by prolyl hydroxylases (PHDs), recognized by the von Hippel-Lindau (VHL) protein, and degraded by the proteasome. The therapeutic gene remains "OFF."
- Under Hypoxia: PHDs are inactivated. HIF-1α stabilizes, translocates to the nucleus, and binds to the HREs in our viral vector, initiating high-level transcription of the transgene.
Construction of Hypoxia-inducible Adenoviral Vectors
The hypoxia-induced system has been incorporated into adenoviral vectors for brain and tumors and has shown considerable promise as a strategy for treating cerebral ischemia and tumors. In hypoxia-inducible expression systems, HREs is commonly used to construct inducible adenoviral vectors to express therapeutic genes for the treatment of diseases. Several studies have used HREs sequences in combination with minimal promoters for adenoviral vectors to limit gene expression in hypoxic tumor environments. In addition, adenoviral vectors selectively mediate hypoxia-inducible gene expression in neurons. For example, a combination of neuron restrictive silencer elements (NRSEs), HREs and CMV minimal promoter (CMVmp) is packaged into replication-defective adenovirus to target gene expression selectively in neurons in a hypoxia-regulated manner. The use of HREs to drive transgene expression in adenoviral vectors has the following advantages:
- The HREs can act as an enhancer to enhance the transcriptional activity of the promoter.
- The HREs can achieve increased tumor selectivity by targeting the hypoxic environment encountered in tumors.
- The incorporation of HREs and hypoxia targeting could broaden the therapeutic efficacy of adenovirus.
Figure 1. Versions of adenoviral vectors and potential therapeutic applications.1
Application
Studies have demonstrated the potential of hypoxia-inducible adenoviral vectors in tumor-selective gene therapy. Solid tumors, characterized by the presence of hypoxic regions, constitute approximately 90% of cancers and are suitable targets for hypoxia-inducible gene therapy. Furthermore, these hypoxia-inducible adenoviral vectors can be a good complement to current cancer treatments. For example, hypoxia-inducible gene expression can be applied to gene radiation therapy using a radiation responsive element with HREs sequence as hypoxia- and radiation-inducible promoter to reduce the tumor tissue resistance to radiation therapies and chemotherapeutic drugs. Application of hypoxia-inducible adenoviral vectors is not limited to cancer treatment, and it is often used to treat other ischemic diseases in which hypoxia is a common feature, such as ischemic heart disease and ischemic stroke.
Services at Creative Biolabs
As the world's leading provider of viral vectors development service, Creative Biolabs has established a variety of adenoviral vectors construction platforms and technology. Based on this, we provide hypoxia-inducible adenoviral vector construction services to enhance the gene therapy effect of adenovirus. Moreover, other regulated adenoviral vector construction services are also available at Creative Biolabs, including:
- Radiation-induced Adenovirus Vector Construction
- Heat-induced Adenovirus Vector Construction
- Tetracycline-inducible Adenovirus Vector Construction
- FK506/Rapamycin-inducible Adenovirus Vector Construction
Our Service Packages
| Component | Standard Package | Advanced Package | Premium Package |
|---|---|---|---|
| Vector Design | Basic HRE promoter | Optimized promoter library | Fully customized regulatory system |
| Viral Titer | ≥1×10¹⁰ vp/mL | ≥5×10¹⁰ vp/mL | ≥1×10¹¹ vp/mL |
| Validation | Basic expression test | Hypoxia vs normoxia assay | Multi-model validation |
| Timeline | 4–6 weeks | 3–4 weeks | 2–3 weeks |
| Support | Standard | Priority | Dedicated project manager |
What You'll Receive
| Deliverable | Description |
|---|---|
| ✓ Custom Adenoviral Vector | Fully constructed hypoxia-inducible vector |
| ✓ High-Titer Viral Stock | Ready-to-use viral particles |
| ✓ Sequence Verification Report | Confirmed construct integrity |
| ✓ Functional Validation Data | Hypoxia responsiveness demonstrated |
| ✓ Technical Documentation | Protocols and usage guidelines |
| ✓ Ongoing Support | Expert consultation throughout your project |
Our End-to-End Service Workflow
We provide a fully integrated workflow, from concept to delivery:
-
Step 1: Project Consultation & Design
Define therapeutic goals and target disease
Select optimal hypoxia-responsive promoter
Determine vector type (replication-deficient vs oncolytic)
-
Step 2: Vector Construction
Cloning of HRE-driven expression cassette
Integration into adenoviral backbone
Sequence verification
-
Step 3: Viral Packaging & Amplification
HEK293-based packaging system
High-titer viral production
Stability optimization
-
Step 4: Purification & Quality Control
CsCl gradient purification
Viral titer determination (PFU/mL or vp/mL)
Sterility and endotoxin testing
-
Step 5: Functional Validation
Hypoxia induction assays
Expression kinetics profiling
Optional in vitro/in vivo evaluation
Technology Overview: How Hypoxia-Inducible Adenoviral Vectors Work
01. Hypoxia-Responsive Promoter Design
We utilize engineered promoters containing hypoxia-responsive elements (HREs) derived from HIF-regulated genes. These promoters remain inactive under normoxic conditions but are strongly activated under hypoxia.
02. Adenoviral Backbone Engineering
Our vectors are based on optimized adenovirus systems with:
- E1/E3 deletions for safety
- Large cargo capacity
- High gene delivery efficiency
03. Conditional Expression or Replication
Depending on your application, we design:
- Expression vectors: Transgene expression activated under hypoxia
- Conditionally replicative adenoviruses (CRAds): Viral replication restricted to hypoxic cells
04. Functional Validation
Each vector undergoes rigorous validation:
- Hypoxia vs normoxia expression comparison
- Dose-response characterization
- Functional assays in relevant cell models
Comprehensive Analytical Characterization
Every batch of hypoxia-inducible adenovirus undergoes a comprehensive "Identity & Potency" battery of tests in our ISO-certified facilities:
-
Physical & Chemical Profiling
- HPLC-AEX: To determine the ratio of Full-to-Empty capsids.
- Dynamic Light Scattering (DLS): To ensure no viral aggregation, crucial for predictable in vivo distribution.
- Purity: SDS-PAGE with Silver Staining to confirm the absence of non-viral proteins.
-
Biological Potency & Specificity
- In Vitro Hypoxia Induction Assay: Using our specialized Baker Ruskinn Hypoxia Workstations, we test expression at 0.1%, 0.5%, 1%, and 21% O₂.
- Reporter Gene Stability: Confirming the long-term expression profile of the HRE-driven cassette.
- Biodistribution Studies (Preclinical): qPCR-based tracking of viral genomes in the liver, lungs, spleen, and target hypoxic tissue post-injection.
Why Choose Creative Biolabs?
Partnering with Creative Biolabs ensures your hypoxia-inducible program is built on a foundation of precision engineering and clinical-grade standards.
-
Superior Specificity
- Minimized Basal Expression: We utilize proprietary Genetic Insulators and miRNA de-targeting to ensure the transgene remains "OFF" in normoxic tissues, eliminating off-target toxicity.
- Optimized HRE Architecture: Custom-engineered tandem HRE repeats (up to 12x) paired with minimal promoters for a >100-fold induction ratio.
-
Advanced Vector Engineering
- Capsid Tailoring: Beyond standard Ad5, we offer Fiber Chimeras and rare serotypes to bypass pre-existing neutralizing antibodies.
- Large Payload Capacity: Efficiently package complex genetic circuits or dual-therapeutic cassettes up to 8.0 kb.
-
Industrial-Grade Quality & Scalability
- High-Titer Production: Suspension-adapted HEK293 platforms.
- Rigorous Characterization: Every batch is validated via NGS, HPLC-AEX, and RCA-free testing.
- Proven Stability: We guarantee the genetic stability of repetitive HRE sequences through multiple viral passages.
-
End-to-End Scientific Support
- Consultative Approach: Direct access to PhD-level virologists for promoter design and serotype selection.
- Regulatory Ready: Data packages are designed to support IND-enabling studies, including comprehensive Certificates of Analysis (CoA).
Frequently Asked Questions
Q: How does hypoxia activate gene expression?
A: Hypoxia triggers the stabilization of transcription factors such as HIF-1α, which bind to hypoxia-responsive elements (HREs) within the promoter region. This interaction initiates transcription of the downstream gene specifically under low oxygen conditions.
Q: What promoters are used in hypoxia-inducible systems?
A: Commonly used promoters include:
- HRE-based synthetic promoters
- VEGF-derived regulatory elements
- Hybrid promoters combining HREs with minimal promoters
These can be customized depending on expression strength and specificity requirements.
Q: Can these vectors be used in vivo?
A: Yes. Hypoxia-inducible adenoviral vectors are widely used in:
- Tumor models
- Ischemic disease studies
- Preclinical therapeutic research
Their environment-specific activation makes them highly suitable for in vivo applications.
Q: How do you ensure specificity?
A: Specificity is achieved through:
- Hypoxia-responsive promoter design
- Vector engineering
- Controlled delivery strategies
This ensures gene expression is restricted to hypoxic tissues, minimizing off-target effects.
Connect with Us Anytime!
At Creative Biolabs, we combine advanced adenoviral engineering, optimized hypoxia-responsive regulatory elements, and rigorous validation workflows to deliver high-performance vectors tailored to your specific research or therapeutic goals. Whether you are developing next-generation cancer therapies, exploring ischemia-driven regeneration, or investigating hypoxia-related biological mechanisms, our solutions are designed to accelerate your progress with confidence. For more detailed information, please feel free to contact us or directly send us a quote.
Reference
- Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L, et al. High-capacity adenoviral vectors: expanding the scope of gene therapy. International Journal of Molecular Sciences, 2020, 21(10): 3643. https://doi.org/10.3390/ijms21103643 Distributed under Open Access license CC BY 4.0, without modification.
